{"id":3541,"date":"2026-09-02T13:00:00","date_gmt":"2026-09-02T11:00:00","guid":{"rendered":"https:\/\/mumak.me\/?p=3541"},"modified":"2026-09-03T19:28:11","modified_gmt":"2026-09-03T17:28:11","slug":"valuation-analysis-eli-lilly-and-company","status":"publish","type":"post","link":"https:\/\/mumak.me\/en\/research-insights\/valuation-analysis\/valuation-analysis-eli-lilly-and-company\/","title":{"rendered":"Valuation Analysis: Eli Lilly and Company"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\"\"\n\t\t\t<\/div>\n\t\t\t
\n\t\t\t\t

Eli Lilly and Company<\/h4>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\tAnalysis result: 4 out of 5 MUMAKS\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

First published: August 11, 2026<\/strong>
Updated: September 2, 2026 | Market data: intraday September 2, 2026<\/strong><\/p>

Update to the valuation analysis<\/h4>

Since our original analysis of Eli Lilly<\/strong>, the fundamental picture has remained largely unchanged, while analyst expectations and the technical setup have continued to evolve.<\/p>

The analyst consensus remains positive, supported by further regulatory progress and an expanding pipeline; at the same time, short-term technical momentum has weakened, shifting our assessment in Phase 5 from Positive to Negative<\/strong>. <\/p>

This update therefore focuses on analyst views, recent company developments, and technical analysis<\/strong>, while the long-term outlook for Eli Lilly remains unchanged.<\/p>

Eli Lilly is one of the world’s leading pharmaceutical companies. The business focuses on diabetes, obesity, and other metabolic diseases. Furthermore, the company is active in the fields of oncology, immunology, and neuroscience. <\/p>

Eli Lilly recorded strong revenue and earnings growth in the second quarter of 2026. Mounjaro and Zepbound are the primary growth drivers, and the full-year guidance was raised once again. <\/p>

Key risks include the high valuation, increasing price pressure in the US, as well as significant expenditures for expanding production capacities and for acquisitions.<\/p>

Rating<\/h2>

This analysis evaluates Eli Lilly and Company according to the UMBRELLA strategy using the MUMAK method. The assessment is carried out across five decision-making phases: Geopolitics<\/strong>, Industry<\/strong>, Fundamentals<\/strong>, Market Sentiment<\/strong>, and Technical Analysis.<\/strong> <\/span><\/p>

The goal is not to predict the future precisely. The goal is orientation. We contextualize facts, demonstrate causal relationships, and structure a comprehensible decision logic. <\/span> <\/span><\/p>

We explain \u2013 you decide.<\/span><\/b> <\/span><\/p>

Geopolitics<\/h3>

Classification <\/strong><\/h4>

Eli Lilly operates at the intersection of health policy, pharmaceutical regulation, and strategically important drug production.<\/p>

The company continues to expand its production network in the US. An additional $4.5 billion<\/strong> has been allocated for production sites in Indiana. This reduces supply chain and customs risks while simultaneously strengthening domestic drug production. <\/p>

Obesity and diabetes are also increasingly gaining importance as central public health challenges. Broader access to treatments and improved reimbursement could significantly increase the number of patients treated. <\/p>

Opportunities<\/strong><\/h5>